NIPH Clinical Trials Search

Basic Information

Recruitment status
Health condition(s) or Problem(s) studied	systemic lupus erythematosus (SLE)
Date of first enrollment	10/06/2013
Target sample size
Countries of recruitment
Study type	Interventional
Intervention(s)	investigational material(s) Generic name etc : LY2127399 INN of investigational material : Therapeutic category code : 399 Agents affecting metabolism, n.e.c. Dosage and Administration for Investigational material : LY2127399 given as a loading dose of 240 mg at Week 0, followed by 120 mg Q2W or 120 mg Q4W if participant received placebo in BCDS study.LY2127399 given as a loading dose of 120 mg at Week 0, followed by 120 mg Q2W or 120 mg Q4W if participant received LY2127399 in BCDS study.

Outcome(s)

Primary Outcome
Secondary Outcome

Key inclusion & exclusion criteria

Age minimum	>= 18age old
Age maximum	Not applicable
Gender	Both
Include criteria	Have completed 52 weeks of treatment in BCDS study
Exclude criteria